Compile Data Set for Download or QSAR
Report error Found 1151 of ec50 for UniProtKB: P03952
TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454990(US10730874, Compound I-14 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454991(US10730874, Compound I-15 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454989(US10730874, Compound I-13 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454986(US10730874, Compound I-10 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454984(US10730874, Compound I-8 | US11352356, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454966(US10730874, Compound I-5 | US11352356, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454849(US10730874, Compound I-2 | US10730874, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455007(US10730874, Compound I-31 | US10730874, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454999(US10730874, Compound I-23 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455020(US10730874, Compound I-44 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455019(US10730874, Compound I-43 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455016(US10730874, Compound I-40 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455041(US10730874, Compound I-65 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454966(US10730874, Compound I-5 | US11352356, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454984(US10730874, Compound I-8 | US11352356, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455036(US10730874, Compound I-60 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454986(US10730874, Compound I-10 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455035(US10730874, Compound I-59 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455033(US10730874, Compound I-57 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454990(US10730874, Compound I-14 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454989(US10730874, Compound I-13 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455028(US10730874, Compound I-52 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454991(US10730874, Compound I-15 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455026(US10730874, Compound I-50 | US10730874, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455027(US10730874, Compound I-51 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455056(US10730874, Compound I-80 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455057(US10730874, Compound I-81 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455054(US10730874, Compound I-78 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455052(US10730874, Compound I-76)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455051(US10730874, Compound I-75 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455049(US10730874, Compound I-73 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455047(US10730874, Compound I-71 | US10730874, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455044(US10730874, Compound I-68 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454849(US10730874, Compound I-2 | US10730874, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455042(US10730874, Compound I-66 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455073(US10730874, Compound I-97 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455016(US10730874, Compound I-40 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455068(US10730874, Compound I-92 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455069(US10730874, Compound I-93 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM454849(US10730874, Compound I-2 | US10730874, Compound I-...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455020(US10730874, Compound I-44 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455019(US10730874, Compound I-43 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455062(US10730874, Compound I-86)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455063(US10730874, Compound I-87)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455061(US10730874, Compound I-85 | US11352356, Compound I...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM557388(US11352356, Compound I-50)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/10/2022
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455088(US10730874, Compound I-109 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455089(US10730874, Compound I-110 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455086(US10730874, Compound I-107 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Shire Human Genetic Therapies

US Patent
LigandPNGBDBM455087(US10730874, Compound I-108 | US11352356, Compound ...)
Affinity DataEC50: <1nMAssay Description:Example compounds were evaluated for inhibition of the human activated kallikrein enzyme in two formats of an assay employing a fluorogenic peptide s...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2021
Entry Details
US Patent

Displayed 1 to 50 (of 1151 total ) | Next | Last >>
Jump to: